United States - English - NLM (National Library of Medicine)

eli lilly and company - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin r is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. humulin r is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] - in patients with hypersensitivity to humulin r or any of its excipients [see warnings and precautions (5.5)] risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7% and has been reported to be as high as 20-25% in women with a hba1c >10%. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general p

United States - English - NLM (National Library of Medicine)

eli lilly and company - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.5)] . risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7% and has been reported to be as high as 20-25% in women with a hba1c >10%. the estimated background risk of miscarriage for the indicated population is unkn

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - insulin soluble human; insulin isophane human - suspension for injection - 30unit/1ml ; 70unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - insulin isophane human - suspension for injection - 100unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - insulin soluble human; insulin isophane human - suspension for injection - 30unit/1ml ; 70unit/1ml

Malta - English - Medicines Authority

eli lilly & co. limited - insulin human (rdna) - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Malta - English - Medicines Authority

eli lilly & co. limited - insulin human (rdna) - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - insulin human, rdna - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes

United States - English - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is an intermediate-acting recombinant human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline a

United States - English - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin 70/30 is a fixed ratio premix recombinant human insulin formulation indicated to improve glycemic control in adult patients with diabetes mellitus. humulin 70/30 is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)], and - in patients who have had hypersensitivity reactions to humulin 70/30 or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly de